Superworth

Praxis Precision Medicines free cash flow PRAX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$305.4M
Latest quarter, Q2 FY26
−$77.8M
Fiscal year 2025
−$249.1M

Praxis Precision Medicines' free cash flow was −$305.4M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$77.8M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$249.1Mn/a
FY2024n/an/a
FY2023−$111.2Mn/a
FY2022−$185.5Mn/a
FY2021−$125.6Mn/a
FY2020−$52.6Mn/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$77.8Mn/a−$305.4M
Q1 FY26−$86.2Mn/a−$282.3M
Q4 FY25−$76.3Mn/a−$249.1M
Q3 FY25−$65.1Mn/a−$228.9M
Q2 FY25−$54.7Mn/a−$191.4M
Q1 FY25−$53Mn/an/a
Q4 FY24−$56.1Mn/an/a
Q3 FY24−$27.5Mn/an/a
Q4 FY23−$23.9Mn/a−$111.2M
Q3 FY23−$23.2Mn/a−$116.1M
Q2 FY23−$31.2Mn/a−$137.8M
Q1 FY23−$32.8Mn/a−$163.9M

Against its peers

Companies in Drug Manufacturers - General nearest Praxis Precision Medicines' size, closest first, today.

CompanyFree cash flow yield
PRAXPraxis Precision Medicines−4.3%
ALKSAlkermes plc.3.0%
AMRXAmneal Pharmaceuticals2.0%
LGNDLigand Pharmaceuticals2.2%
TGTXTG Therapeutics0.2%
KNSAKiniksa Pharmaceuticals International3.1%
PTGXProtagonist Therapeutics1.5%
CORTCorcept Therapeutics1.2%
BMRNBiomarin Pharmaceutical6.8%
INDVIndivior Pharmaceuticals−2.7%
ARQTArcutis Biotherapeutics1.0%
Peer median1.7%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Praxis Precision Medicines

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.